In 2015 the Montgomery judgment signalled the end of the previous paternalistic system when doctors decided which treatment risks to warn a patient about. The repercussions of this historic ruling could now mean that pharmacists must change they way they interact with patients.
Articles: 29.01 January 2018
In March 2017, the Faculty of Sexual and Reproductive Healthcare issued a new guideline on emergency contraception. This article provides an overview of the current approach to managing emergency contraception to help busy clinicians tailor the most appropriate method to each individual
There is little awareness among pharmacists of the existence of the Montgomery judgment or its potential implications for medicines-related consultations. Nina Barnett and Claudia Carr therefore undertook a survey of pharmacists in England to create a baseline for current knowledge about informed consent in the context of medicines-related consultations.
Orphan drugs can transform the lives of patients with rare diseases, but they often come at an extremely high cost. Sarah Houlton discusses the incentives that are encouraging pharma investment in orphan drug research and the steps that NICE and the NHS are taking to budget for these treatments as they come to market
The British Society for Rheumatology published a revised and updated guideline on the management of gout in July 2017, the first in a decade. This article summarises the main recommendations of the new guideline
In September 2017, the Royal College of Obstetricians and Gynaecologists published their updated Green-top Guideline on the prevention of early-onset neonatal group B streptococcal disease. Here, Dr Williams summarises some of the main changes to the guidance and their implications for antenatal and peripartum care
Dimethyl fumarate (Skilarence) is an oral therapy licensed for the treatment of moderate to severe plaque psoriasis in adults when systemic treatment is indicated. This article discusses its efficacy, adverse effects and place in therapy